Hikma Pharmaceuticals PLC (LON:HIK)
London · Delayed Price · Currency is GBP · Price in GBX 1,585.00
-9.00 (-0.56%)
Jul 31, 2026, 5:13 PM GMT
Hikma Pharmaceuticals Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Operating Activities
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | 519 | 455 | 281 | 233 | 544 |
Depreciation & Amortization | 238 | 168 | 259 | 372 | 145 |
Stock-Based Compensation | 23 | 27 | 25 | 22 | 29 |
Other Adjustments | 31 | 174 | 92 | 89 | 77 |
Change in Receivables | -97 | -144 | -24 | 4 | -166 |
Changes in Inventories | -86 | -112 | -115 | -102 | 38 |
Changes in Accounts Payable | 38 | 78 | 88 | 16 | 14 |
Changes in Income Taxes Payable | -124 | -125 | -129 | -55 | -129 |
Changes in Other Operating Activities | -106 | 43 | 131 | -49 | 86 |
Operating Cash Flow | 436 | 564 | 608 | 530 | 638 |
Operating Cash Flow Growth | -22.70% | -7.24% | 14.72% | -16.93% | 37.50% |
Investing Activities
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Capital Expenditures | -197 | -165 | -169 | -138 | -145 |
Sale of Property, Plant & Equipment | - | - | 18 | 1 | - |
Purchases of Intangible Assets | -120 | -70 | -35 | -87 | -84 |
Proceeds from Sale of Intangible Assets | - | - | - | 9 | - |
Purchases of Investments | -3 | -2 | -27 | -15 | -3 |
Proceeds from Sale of Investments | - | - | 1 | - | 5 |
Cash Acquisitions | -75 | -162 | -128 | -379 | -17 |
Proceeds from Business Divestments | - | 10 | - | -1 | 1 |
Other Investing Activities | 7 | 8 | 7 | 3 | 5 |
Investing Cash Flow | -388 | -381 | -333 | -607 | -238 |
Financing Activities
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Short-Term Debt Issued | 349 | 387 | 437 | 380 | 383 |
Short-Term Debt Repaid | -357 | -411 | -467 | -363 | -431 |
Net Short-Term Debt Issued (Repaid) | -8 | -24 | -30 | 17 | -48 |
Long-Term Debt Issued | 2,402 | 684 | 778 | 1,401 | 10 |
Long-Term Debt Repaid | -2,093 | -536 | -841 | -962 | -45 |
Net Long-Term Debt Issued (Repaid) | 309 | 148 | -63 | 439 | -35 |
Repurchase of Common Stock | -36 | -38 | - | -300 | - |
Net Common Stock Issued (Repurchased) | -36 | -38 | - | -300 | - |
Common Dividends Paid | -185 | -175 | -137 | -125 | -120 |
Other Financing Activities | -105 | -99 | -107 | -89 | -84 |
Financing Cash Flow | -25 | -188 | -337 | -58 | -287 |
Net Cash Flow
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Foreign Exchange Rate Adjustments | 6 | -12 | -3 | -21 | -10 |
Net Cash Flow | 23 | -5 | -62 | -135 | 113 |
Free Cash Flow
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 239 | 399 | 439 | 392 | 493 |
Free Cash Flow Growth | -40.10% | -9.11% | 11.99% | -20.49% | 68.84% |
FCF Margin | 7.14% | 12.76% | 15.27% | 15.57% | 19.31% |
Free Cash Flow Per Share | 1.07 | 1.79 | 1.97 | 1.74 | 2.12 |
Levered Free Cash Flow | 466 | 370 | 162 | 688 | 347 |
Unlevered Free Cash Flow | 188.04 | 373.91 | 315.76 | 275.17 | 458.34 |